DCF Advisers LLC purchased 9,250 shares of Regeneron Pharmaceuticals, valued at approximately $5.77 million. This stake represents 1.0% of DCF Advisers' portfolio. Regeneron becomes its 14th largest holding. Institutional investors own 83.31% of the company's stock.
A day earlier, Regeneron announced FDA approval for Pasatru. This new treatment addresses the ultra-rare bone disorder FOP. The company also faces a securities class action lawsuit related to its Phase 3 fianlimab-Libtayo melanoma trial. The lead-plaintiff deadline is September 14, 2026.